![Global shares jump on Trump's AI push, dollar at two-week low](https://i-invdn-com.investing.com/news/external-images-thumbnails/LYNXNPEL0K034_L.jpg)
Please try another search
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Napoleone Ferrara | 67 | 2014 | Member of Scientific Advisory Board |
Willy Jules Simon | 73 | 2015 | Independent Non-Executive Director |
Howard L. Weiner | 77 | 2016 | Chairman of Scientific Advisory Board |
Kevan Herold | - | 2016 | Member of Scientific Advisory Board |
John Patrick Brancaccio | 76 | 2020 | Independent Non-Executive Director |
Arun J. Sanyal | - | 2017 | Member of Scientific Advisory Board |
Ivor R. Elrifi | - | 2024 | CEO & Executive Director |
Gabriele Marco Antonio Cerrone | 52 | 2014 | Founder & Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review